

Begin forwarded message:

From: Nancy Olivieri <nancy@hemoglobal.org>

Subject: A letter from Drs. Gallie and Olivieri

Date: March 27, 2019 at 5:30:20 AM EDT

To: "Baker, Michael Dr." <Michael.Baker@uhn.ca>, "Smith, Kevin" <Kevin.Smith@uhn.ca>

Cc: Gallie Brenda <brenda@gallie.ca>, Olivieri Nancy <nancy@hemoglobal.org>

Dear Drs. Baker and Smith,

Please find attached a letter from Dr. Gallie and myself.

Further to this letter and as outlined in our previous letter dated 13 March 2019, we will be sending anonymized documents, summaries and data to Dr. Baker for his review of patient care, including (as requested):

- A clinical summary of the patient's history including within the relevant period of deferiprone administration;
- A (one-page) summary of clinical and laboratory findings for each interval of deferiprone exposure;
- When relevant, a graph of changes in liver enzymes over the relevant period(s) of deferiprone exposure.
- Any additional relevant material Dr. Baker has requested, or may later request, to facilitate review of the use of unlicensed deferiprone at UHN.

Sincerely,

Nancy

Nancy F. Olivieri, MD, MA, FRCP(C)
Professor, Pediatrics, Medicine and Public Health Sciences,
University of Toronto, Canada;
Senior Scientist, Toronto General Hospital,
200 Elizabeth Street, Eaton Wing North 7-227
Toronto, Ontario Canada M5G 2C4

Executive Director, Hemoglobal®

www.hemoglobal.org

Tel: 647-299-6935

Email: nancy@hemoglobal.org